As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.
12 Analysts have issued a Neoleukin Therapeutics Inc forecast:
12 Analysts have issued a Neoleukin Therapeutics Inc forecast:
| Dec '24 | 
         
    +/-
   
  
    %
   
 | 
      ||
| Revenue | 0.93 0.93 | 
         
    -
 
        
       | 
      |
| Gross Profit | - - | 
         
    -
 
        
       | 
      |
| EBITDA | -79 -79 | 
         
      
        
        62%
      
      
        
        62%
      
 
        
       | 
      |
| EBIT (Operating Income) EBIT | -83 -83 | 
         
      
        
        58%
      
      
        
        58%
      
 
        
       | 
      |
| Net Profit | -75 -75 | 
         
      
        
        107%
      
      
        
        107%
      
 
        
       | 
      |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
| Head office | United States | 
| CEO | Rachel McMinn | 
| Employees | 107 | 
| Founded | 2018 | 
| Website | www.neurogene.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


